Advances in pharmacotherapy of small cell lung cancer

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 16, 2014, Pages 2385-2396

  Kalemkerian, Gregory P ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Carboplatin; Chemotherapy; Cisplatin; Etoposide; Irinotecan; Molecularly targeted therapy; Radiotherapy; Small cell lung cancer

Indexed keywords

ALKYLATING AGENT; AMRUBICIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IRINOTECAN; PACLITAXEL; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; HUMAN; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMALL CELL LUNG CANCER; SURVIVAL TIME; ANIMAL; LUNG NEOPLASMS; METABOLISM; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; SMALL CELL LUNG CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMALL CELL LUNG CARCINOMA;

EID: 84911472338     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.957180     Document Type: Review

References (99)

1. Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer: relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer 2012;131:1210-19
2. Churg A. Lung cancer cell type and occupational exposure. In: Samet JM, editor. Epidemiology of lung cancer. Marcel Dekker, New York; 1994. p. 413-36
3. Navada S, Lai P, Schwartz AG, Kalemkerian GP. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results database. J Clin Oncol 2006;24(18S):384s
4. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of smallcell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End-Results database. J Clin Oncol 2006;24:4539-44
5. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-19
6. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973;4:31-42
7. Goldstraw P, Crowley JJ, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification for malignant tumors. J Thorac Oncol 2007;2:706-14
8. Shepherd FA, Crowley J, Van Houtte P, et al. The IASLC Lung Cancer Staging Project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067-77
9. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-24
10. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung A meta-analysis. J Clin Oncol 1992;10:890-5
11. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limitedstage small cell lung cancer. J Clin Oncol 2004;22:4785-93
12. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71
13. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999;341:476-84
14. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357:664-72
15. Hanna NH, Einhorn LH. Small-cell lung cancer: state of the art. Clin Lung Cancer 2002;4:87-94
16. Greco FA, Oldham RK. Clinical management of patients with small cell lung cancer. In: Greco FA, Oldham RK, Bunn PA, editors. Small cell lung cancer. Grune & Stratton, New York; 1981. p. 353-79
17. Lowenbraun S, Bartolucci A, Smalley RV, et al. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 1979;44:406-13
18. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434-41
19. Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985;3:1471-7
20. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855-61
21. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-91
22. Sundstrøm S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665-72
23. Pujol JL, Carestia L, Duares JP. Is there a case for cisplatin in the treatment of small-cell lung cancer A meta-analysis of randomized trials of a cisplatincontaining regimen versus a regimen without this alkylating agent. Br J Cancer 2000;83:8-15
24. Mascaux C, Paesmans M, Breghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000;30:23-36
25. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-801
26. Postmus PE, Berendsen HH, van Zandwijk N, et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987;23:1409-11
27. Giaccone G, Ferrati P, Donadio M, et al. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987;23:1697-9
28. O'Brien MER, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7
29. Von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67
30. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91
31. Hanna N, Bunn PA, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.J Clin Oncol. 2006;24:2038-43
32. Lara PN, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-5
33. Zatloukal P, Cardenal F, Szxzesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 2010;21:1810-16
34. Kubota K, Hida T, Ishikura S, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limitedstage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomized phase 3 study. Lancet Oncol 2013;15:106-13
35. Hermes A, Bergman B, Bremmew R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008;26:4261-7
36. Schmittel A, von Weikersthal LF, Sebastian M, et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 2006;17:663-7
37. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cislplatin versus etoposide/cisplatin as treatment for chemotherapynaive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006;24:2044-51
38. Fink TH, Huber RM, Heigener DF, et al. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease smallcell lung cancer. J Thorac Oncol 2012;7:1432-9
39. Jiang J, Liang X, Zhou X, et al. A metaanalysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010;5:867-73
40. Lima JP, dos Santos LV, Sasse EC, et al. Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. J Thorac Oncol 2010;5:1986-93
41. Thomas P, Castelnau O, Paillotin D, et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Francais de Pneumo-Cancerologie study. J Clin Oncol 2001;19:1320-5
42. Lyss AP, Herndon JE, Lynch TJ, et al. Novel doublets in extensive-stage smallcell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel. Clin Lung Cancer 2002;3:205-10
43. Leyvraz S, Pampallona S, Martinelli G, et al. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst 2008;100:533-41
44. Lorigan P, Woll PJ, O'Brien MER, et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in betterprognosis small-cell lung cancer. J Natl Cancer Inst 2005;97:666-74
45. Furuse K, Fukuoka M, Nishiwaki Y, et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. J Clin Oncol 1998;16:2126-32
46. Niell HB, Herndon JE, Miller AA, et al. Randomized phase III Intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colonystimulating factor in patients with extensive-stage small-cell lung cancer: cancer and Leukemia Group B trial 9732. J Clin Oncol 2005;23:3752-9
47. Elias A, Ibrahim J, Skarin AT, et al. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol 1999;17:1175-84
48. Rossi A, Garassino MC, Cinquini M, et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010;70:119-28
49. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114-22
50. Sklaros DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposidecarboplatin and irradiation in small-cell lung cancer. Ann Oncol 1994;5:601-7
51. Rossi A, DiMaio M, Chiodini P, et al. Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS metaanalysis of individual patient data. J Clin Oncol 2012;30:1692-8
52. Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: west Japan Thoracic Oncology Group study. Invest New Drugs 2007;25:253-8
53. Ohe Y, Negoro S, Matsui K, et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small cell lung cancer. Ann Oncol 2005;16:430-6
54. Satouchi M, Kotani Y, Shibata T, et al. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensivedisease small-cell lung cancer: JCOG 0509. J Clin Oncol 2014;32:1262-8
55. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for the treatment of refractory or relapsed smallcell lung cancer: thoracic Oncology Research Group study 0301. J Clin Oncol 2006;24:5448-53
56. Igawa S, Yamamoto N, Ueda S, et al. Evaluation of the recommended dose and efficacy of amrubicin as second-and third-line chemotherapy for small cell lung cancer. J Thorac Oncol 2007;2:741-4
57. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as secondline therapy in patients with platinumrefractory small-cell lung cancer. J Clin Oncol 2010;28:2598-603
58. Shimokawa T, Shibuya M, Kitamura K, et al. Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer. Int J Clin Oncol 2009;14:63-9
59. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: north Japan Lung Cancer Study Group trial 0402. J Clin Oncol 2008;26:5401-6
60. Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinumbased chemotherapy. J Clin Oncol 2011;29:287-93
61. Jotte R, von Pawel J, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer. J Clin Oncol 2011;29(15S):453s
62. Rudin CM, Hann CL, Peacock CD, Watkins DN. Novel systemic therapies for small cell lung cancer. J Natl Compr Canc Netw 2008.6:315-22
63. Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-10
64. Rudin CM, Durnick S, Stawiski EW, et al. Comprehensive gneomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012;44:1111-16
65. Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012;2:798-811
66. Sos ML, Dietlein F, Peifer M, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci USA 2012;109:17034-9
67. Lassen UN, Hirsh FR, Osterlind K, et al. Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress Lung Cancer 1998;20:151-60
68. Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating microemboli in patients with small-cell lung cancer. J Clin Oncol 2012;30:525-32
69. Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011;29:2215-22
70. Pujol JL, Lavole A, Quoix E, et al. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: IFCT-0802 trial. J Clin Oncol 2014;32(15S):478s
71. Allen JW, Moon J, Gadgeel SM, et al. SWOG 0802: a randomized phase II trial of weekly topotecan with and without AVE0005 (aflibercept) in patients with platinum-treated extensivestage small cell lung cancer. J Clin Oncol 2012;30(15S):453s
72. Pujol JL, Breton JL, Gervais R, et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an Intergroup Study FNCLCC cleo04-IFCT 00-01. J Clin Oncol 2007;25:3945-51
73. Lee SM, Woll PJ, Rudd R, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo controlled trial. J Natl Cancer Inst 2009;101:1049-57
74. Schneider BJ, Gadgeel SM, Ramnath N, et al. Phase II trial of sunitinib maintenance therapy after platinumbased chemotherapy in patients with extensive-stage small cell lung cancer. J Thorac Oncol 2011;6:1117-20
75. Han JY, Kim HY, Lim KY, et al. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer 2013;79:137-42
76. Gitlitz BJ, Moon J, Glisson BS, et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer. J Thorac Oncol 2010;5:1835-40
77. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007;25:4278-84
78. Ramalingam SS, Belani CP, Mack PC, et al. Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol 2010;5:1279-84
79. Schneider BJ, Kalemkerian GP, Ramnath N, et al. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit-positive, extensive-stage small-cell lung cancer. Clin Lung Cancer 2010;11:223-7
80. Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trial of imatinib (STI571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005;6.1811-6
81. Miller AA, Pang H, Hodgson L, et al. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol 2010;5:380-4
82. Moore AM, Einhorn LH, Estes D, et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006;52:93-7
83. Pandya KJ, Dahlberg S, Hidalgo M, et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007;2:1036-41
84. Heymach JV, Johnson DH, Khuri FR, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapsed small-cell lung cancer. Ann Oncol 2004;15:1187-93
85. Belani CP, Dahlberg SE, Rudin CM, et al. Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib or cixitumumab for patients with extensivestage small cell lung cancer (ECOG 1508). J Clin Oncol 2013;31(15S):460s
86. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, doubleblind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002;20:4434-9
87. Rigas JR, Denham CA, Rinaldi DA, et al. Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor, BAY12-9566, as adjuvant therapy for patients with small cell and non-small cell lung cancer. Proc Am Soc Clin Oncol 2003;22:628
88. Rudin CM, Salgia R, Wang X, et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensivestage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008;26:870-6
89. Paik PK, Rudin CM, Pietanza MC, et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 2011;74:481-5
90. Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012;18:3163-9
91. Baggstrom MQ, Qi Y, Koczywas M, et al. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol 2011;6:1757-60
92. Kalemkerian GP, Jiroutek M, Ettinger DS, et al. A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in extensive stage small cell lung cancer: an Eastern Cooperative Oncology Group study. Cancer 1998;83:1102-8
93. Schneider BJ, Worden FP, Gadgeel SM, et al. Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Invest New Drugs 2009;27:571-8
94. Otterson GA, Hodgson L, Pang H, et al. Phase II study of the histone deacetylase inhibitor romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol 2010;5:1644-8
95. Melichar B, Adenis A, Havel L, et al. Phase I/II study of investigational Aurora A kinase inhibitor MLN8237 (alisertib): updates ph II results in patients with small cell lung cancer, non-SCLC, breast cancer, head and neck squamous cell carcinoma, and gastroesophageal cancer. J Clin Oncol 2013;31(15S):33s
96. Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/Bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971B; Silva Study). J Clin Oncol 2005;23:6854-64
97. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013;24:75-83
98. Rudin CM, Poirier JT, Senzer NN, et al. Phase I clinical study of Seneca Valley Virus (SVV-001), a replicationcompetent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res 2011;17:888-95
99. Molina JR, Mandrekar SJ, Dy GK, et al. A randomized double-blind phase II study of the Seneca Valley virus (NTX-010) versus placebo for patients with extensive stage SCLC who were stable or responding after at least four cycles of platinum-based chemotherapy: Alliance (NCCTG) N0923 study. J Clin Oncol 2013;31(15S):460s